Not yet recruitingPhase 3NCT06465472

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3

Studying Primary hyperoxaluria type 1

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biocodex
Principal Investigator
Oana BERNARD, MD, M.D
Chief Scientific Officer
Intervention
Stiripentol Oral Capsule(drug)
Enrollment
42 enrolled
Eligibility
6 years · All sexes
Timeline
2024 – 2030

Collaborators

Exystat

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06465472 on ClinicalTrials.gov

Other trials for Primary hyperoxaluria type 1

Additional recruiting or active studies for the same condition.

See all trials for Primary hyperoxaluria type 1 →

← Back to all trials